Program
sotevtamab
Also written as “Sotevtamab” and “AB-16B5”.
Its studies are mostly in Pancreatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Neoplasm Metastasis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alethia Biotherapeutics | 31 open or running | phase 2since Apr 23, 2020 | Mar 30, 2015 | none ahead |
| ImmunityBio | 10 open or running | phase 1since Nov 20, 2025 | Nov 20, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 30, 2015First study: phase 1 study in Neoplasm MetastasisNew to Alethia BiotherapeuticsAlethia Biotherapeutics · NCT02412462 · 15 enrolled · Canada
- Apr 23, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungAlethia Biotherapeutics · NCT04364620 · 35 enrolled · United States, Canada
- Nov 17, 2023Phase 2 study in Colorectal NeoplasmsAlethia Biotherapeutics · NCT06225843 · 17 planned · Canada
- Nov 20, 2025ImmunityBio's first study: phase 1 study in Pancreatic NeoplasmsNew to ImmunityBioImmunityBio · NCT07488884
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07488884Pancreatic Neoplasms | 1 | Withdrawn | ImmunityBio | Jun 1, 2027 | 0 |
| NCT06225843Colorectal Neoplasms · Canada | 2 | Recruiting | Alethia Biotherapeutics | Mar 2026 | 17 |
| NCT04364620Carcinoma, Non-Small-Cell Lung · United States, Canada | 2 | Completed | Alethia Biotherapeutics | Dec 31, 2023 | 35 |
| NCT02412462Neoplasm Metastasis · Canada | 1 | Completed | Alethia Biotherapeutics | Jan 2017 | 15 |
How it is read
Names in the registry
- “Sotevtamab”, 2 entries
- “AB-16B5”, 2 entries
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Colorectal Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.